Virus Against Virus: Strategies for Using Adenovirus Vectors in the Treatment of Hpv-Induced Cervical Cancer Publisher Pubmed



Ghanaat M¹ ; Goradel NH² ; Arashkia A³ ; Ebrahimi N⁴ ; Ghorghanlu S² ; Malekshahi ZV² ; Fattahi E⁵ ; Negahdari B² ; Kaboosi H¹ Show Affiliations
Source: Acta Pharmacologica Sinica Published:2021

Abstract

Although most human papillomavirus (HPV) infections are harmless, persistent infection with high-risk types of HPV is known to be the leading cause of cervical cancer. Following the infection of the epithelium and integration into the host genome, the oncogenic proteins E6 and E7 disrupt cell cycle control by inducing p53 and retinoblastoma (Rb) degradation. Despite the FDA approval of prophylactic vaccines, there are still issues with cervical cancer treatment; thus, many therapeutic approaches have been developed to date. Due to strong immunogenicity, a high capacity for packaging foreign DNA, safety, and the ability to infect a myriad of cells, adenoviruses have drawn attention of researchers. Adenovirus vectors have been used for different purposes, including as oncolytic agents to kill cancer cells, carrier for RNA interference to block oncoproteins expression, vaccines for eliciting immune responses, especially in cytotoxic T lymphocytes (CTLs), and gene therapy vehicles for restoring p53 and Rb function. © 2021, The Author(s), under exclusive licence to CPS and SIMM.